AR063697A1 - DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA - Google Patents
DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIAInfo
- Publication number
- AR063697A1 AR063697A1 ARP070103808A AR063697A1 AR 063697 A1 AR063697 A1 AR 063697A1 AR P070103808 A ARP070103808 A AR P070103808A AR 063697 A1 AR063697 A1 AR 063697A1
- Authority
- AR
- Argentina
- Prior art keywords
- bifeprunox
- schizophrenia
- patient
- compound
- treatment
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una dosis diaria de bifeprunox para el tratamiento de un paciente con esquizofrenia. Tal dosis es efectivamente utilizada en métodos para tratar esquizofrenia que comprenden administrar a un paciente una composición farmacéutica que comprende una cantidad efectiva de al menos un compuesto de bifeprunox, entre otros efectos, dando por resultado una reducción de los efectos secundarios asociados con el tratamiento de la esquizofrenia, tales como: no aumento de peso, mejoría en los niveles de triglicéridos no en ayunas y/o en los niveles de colesterol total. Los efectos del tratamiento son por ej., una reducción en el puntaje total de la PANSS en un paciente y un incremento del tiempo de deterioro de la esquizofrenia y mejoría en los síntomas psicóticos. Reivindicación 28: Bifeprunox para el uso de una cualquiera de las reivindicaciones 19-27, en donde al menos un compuesto de bifeprunox es administrado en combinación con la droga estabilizante del humor litio. Reivindicación 30: Bifeprunox para uso de una cualquiera de las reivindicaciones 19-27, en donde al menos un compuesto de bifeprunox es administrado en combinación con un antidepresivo.A daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such a dose is effectively used in methods to treat schizophrenia which comprise administering to a patient a pharmaceutical composition comprising an effective amount of at least one compound of bifeprunox, among other effects, resulting in a reduction of the side effects associated with the treatment of schizophrenia, such as: no weight gain, improvement in non-fasting triglyceride levels and / or total cholesterol levels. The effects of the treatment are, for example, a reduction in the total PANSS score in a patient and an increase in the time of deterioration of schizophrenia and improvement in psychotic symptoms. Claim 28: Bifeprunox for the use of any one of claims 19-27, wherein at least one compound of bifeprunox is administered in combination with the lithium mood stabilizing drug. Claim 30: Bifeprunox for use of any one of claims 19-27, wherein at least one compound of bifeprunox is administered in combination with an antidepressant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06119936 | 2006-08-31 | ||
EP06120016 | 2006-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063697A1 true AR063697A1 (en) | 2009-02-11 |
Family
ID=40085736
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103807 AR062561A1 (en) | 2006-08-31 | 2007-08-28 | COMPOSITIONS KITS AND METHODS OF A TITULATION PROGRAM FOR BIFEPRUNOX COMPOUNDS |
ARP070103808 AR063697A1 (en) | 2006-08-31 | 2007-08-28 | DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103807 AR062561A1 (en) | 2006-08-31 | 2007-08-28 | COMPOSITIONS KITS AND METHODS OF A TITULATION PROGRAM FOR BIFEPRUNOX COMPOUNDS |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN101686978A (en) |
AR (2) | AR062561A1 (en) |
MX (2) | MX2009002253A (en) |
TW (2) | TW200829576A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115569123B (en) * | 2022-12-08 | 2023-03-14 | 则正(济南)生物科技有限公司 | Vorinosane fumarate tablet and preparation method thereof |
-
2007
- 2007-08-28 AR ARP070103807 patent/AR062561A1/en not_active Application Discontinuation
- 2007-08-28 AR ARP070103808 patent/AR063697A1/en not_active Application Discontinuation
- 2007-08-28 TW TW96131862A patent/TW200829576A/en unknown
- 2007-08-28 TW TW96131861A patent/TW200817390A/en unknown
- 2007-08-29 MX MX2009002253A patent/MX2009002253A/en not_active Application Discontinuation
- 2007-08-29 MX MX2009002254A patent/MX2009002254A/en not_active Application Discontinuation
- 2007-08-29 CN CN200780032312A patent/CN101686978A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2009002254A (en) | 2009-07-24 |
CN101686978A (en) | 2010-03-31 |
TW200817390A (en) | 2008-04-16 |
MX2009002253A (en) | 2009-06-04 |
TW200829576A (en) | 2008-07-16 |
AR062561A1 (en) | 2008-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507609A (en) | therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
AR054064A1 (en) | COMPOSITION WITH ACTIVE PHARMACEUTICAL INGREDIENT BASED ON CANABINOID FOR IMPROVED DOSE FORMS | |
BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
CO6311007A2 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING AN AGENT THAT ACTIVATES REGULATORY T-CELLS CD4 + CD25 +, EFFECTIVE AT LOW DOSE | |
AR054347A1 (en) | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
EA201490279A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
CO6311006A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN AGENT THAT ACTIVATES THE REGULATORY T-CELLS CD4 + CD25 + HIGH-DOSE EFFECTIVE | |
AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
PE20170302A1 (en) | USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE | |
AR054234A1 (en) | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT | |
AR085662A1 (en) | METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | |
BR112015029401A8 (en) | pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination | |
AR082803A1 (en) | METHODS AND FORMULATIONS FOR THE TREATMENT OF THROMBOSIS WITH BETRIXABAN AND A GLICOPROTEIN P INHIBITOR | |
AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
AR048318A1 (en) | ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA | |
PE20061245A1 (en) | COMPOSITIONS FOR ORAL TRANSMUCOUS TRANSMISSION OF METFORMIN | |
ES2656913T3 (en) | Endrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors | |
CO6220945A2 (en) | USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA | |
CL2021002107A1 (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria. | |
UY30847A1 (en) | USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS | |
AR048370A1 (en) | COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY | |
AR045263A1 (en) | METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS | |
PE20090524A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE INHIBITOR AGENT OF SEROTONIN RECAPTURE | |
AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
AR063697A1 (en) | DOSAGE OF BIFERUNOX TO TREAT SCHIZOPHRENIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |